January 9, 2018 12:49 PM EST

Global Blood Therapeutics' sickle cell disease drug gets breakthrough therapy status; Boehringer Ingelheim will manufacture BeiGene's PD-1 inhibitor in Shanghai

Amber Tong

→ Global Blood Therapeutics just got breakthrough therapy designation from the FDA for its all important sickle cell disease drug, voxelotor (GBT440). The decision …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Global Blood Therapeutics' sickle cell disease drug gets breakthrough therapy status; Boehringer Ingelheim will manufacture BeiGene's PD-1 inhibitor in Shanghai

Amber Tong

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Glob­al Blood Ther­a­peu­tic­s' sick­le cell dis­ease drug gets break­through ther­a­py sta­tus; Boehringer In­gel­heim will man­u­fac­ture BeiGene's PD-1 in­hibitor in Shang­hai

Amber Tong

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Global Blood Therapeutics' sickle cell disease drug gets breakthrough therapy status; Boehringer Ingelheim will manufacture BeiGene's PD-1 inhibitor in Shanghai

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties